|
2024-12-30 |
2024-12-30 |
V
Verkauf
|
Tyree James L
Nicht geschäftsführender Verwaltungsratsmitglied
|
3.460
-7.0%
2,46
8.512 USD
|
3.460
-7.0%
|
2,46
|
8.512 USD
|
|
|
2024-12-18 |
2024-12-16 |
GV
Geplanter Verkauf
|
Zak Lourie S.
Chief Financial Officer
Führungsperson
|
2.103
-4.9%
2,34
4.921 USD
|
2.103
-4.9%
|
2,34
|
4.921 USD
|
|
|
2024-12-18 |
2024-12-16 |
GV
Geplanter Verkauf
|
Smalling Ralph
Head of Regulatory
Führungsperson
|
2.510
-13.3%
2,34
5.873 USD
|
2.510
-13.3%
|
2,34
|
5.873 USD
|
|
|
2024-12-18 |
2024-12-16 |
V
Verkauf
|
Cappello Joseph
VP, Pharmaceutical Development
Führungsperson
|
6.300
-30.1%
2,34
14.742 USD
|
6.300
-30.1%
|
2,34
|
14.742 USD
|
|
|
2024-12-18 |
2024-12-16 |
GV
Geplanter Verkauf
|
Zindrick Thomas
President and CEO
Geschäftsführender Verwaltungsratsmitglied
|
14.315
-27.7%
2,34
33.497 USD
|
14.315
-27.7%
|
2,34
|
33.497 USD
|
|
|
2024-09-13 |
2024-09-13 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
33.080
-5.2%
2,57
84.946 USD
|
33.080
-5.2%
|
2,57
|
84.946 USD
|
|
|
2024-09-13 |
2024-09-12 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
31.777
-4.8%
2,73
86.732 USD
|
31.777
-4.8%
|
2,73
|
86.732 USD
|
|
|
2024-09-12 |
2024-09-11 |
GV
Geplanter Verkauf
|
Tyree James L
Nicht geschäftsführender Verwaltungsratsmitglied
|
1.730
-3.5%
2,60
4.499 USD
|
1.730
-3.5%
|
2,60
|
4.499 USD
|
|
|
2024-09-11 |
2024-09-11 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
31.376
-4.5%
2,62
82.227 USD
|
31.376
-4.5%
|
2,62
|
82.227 USD
|
|
|
2024-09-11 |
2024-09-10 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
20.384
-2.8%
2,51
51.182 USD
|
20.384
-2.8%
|
2,51
|
51.182 USD
|
|
|
2024-09-11 |
2024-09-09 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
23.383
-3.2%
2,70
63.200 USD
|
23.383
-3.2%
|
2,70
|
63.200 USD
|
|
|
2024-09-06 |
2024-09-03 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
42.818
-5.5%
2,09
89.614 USD
|
42.818
-5.5%
|
2,09
|
89.614 USD
|
|
|
2024-08-30 |
2024-08-30 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
142.589
-15.4%
2,17
309.846 USD
|
142.589
-15.4%
|
2,17
|
309.846 USD
|
|
|
2024-08-30 |
2024-08-29 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
107.045
-10.4%
1,98
211.960 USD
|
107.045
-10.4%
|
1,98
|
211.960 USD
|
|
|
2024-08-30 |
2024-08-28 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
15.918
-1.5%
2,05
32.605 USD
|
15.918
-1.5%
|
2,05
|
32.605 USD
|
|
|
2024-08-27 |
2024-08-27 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
51.630
-4.7%
2,11
108.862 USD
|
51.630
-4.7%
|
2,11
|
108.862 USD
|
|
|
2024-08-27 |
2024-08-23 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
40.000
-3.5%
2,29
91.416 USD
|
40.000
-3.5%
|
2,29
|
91.416 USD
|
|
|
2024-07-08 |
2024-06-24 |
V
Verkauf
|
Yu Yong
VP, Clinical Trial Operations
Führungsperson
|
6.849
-38.7%
2,12
14.520 USD
|
6.849
-38.7%
|
2,12
|
14.520 USD
|
|
|
2024-07-08 |
2024-06-24 |
V
Verkauf
|
Jewett Caroline
Head of Quality
Führungsperson
|
4.961
-23.5%
2,12
10.517 USD
|
4.961
-23.5%
|
2,12
|
10.517 USD
|
|
|
2024-07-08 |
2024-06-24 |
GV
Geplanter Verkauf
|
Ryder Sean
General Counsel
Führungsperson
|
5.496
-22.1%
2,12
11.652 USD
|
5.496
-22.1%
|
2,12
|
11.652 USD
|
|
|
2024-05-15 |
2024-05-15 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
17.094
-1.5%
3,66
62.624 USD
|
17.094
-1.5%
|
3,66
|
62.624 USD
|
|
|
2024-05-15 |
2024-05-14 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
15.426
-1.3%
3,58
55.274 USD
|
15.426
-1.3%
|
3,58
|
55.274 USD
|
|
|
2024-05-15 |
2024-05-13 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
3.446
-0.3%
3,62
12.478 USD
|
3.446
-0.3%
|
3,62
|
12.478 USD
|
|
|
2024-05-09 |
2024-05-08 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
13.919
-1.2%
3,82
53.189 USD
|
13.919
-1.2%
|
3,82
|
53.189 USD
|
|
|
2024-05-09 |
2024-05-07 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
6.025
-0.5%
3,67
22.111 USD
|
6.025
-0.5%
|
3,67
|
22.111 USD
|
|
|
2024-05-01 |
2024-05-01 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
33.061
-2.7%
3,30
109.161 USD
|
33.061
-2.7%
|
3,30
|
109.161 USD
|
|
|
2024-05-01 |
2024-04-30 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
20.535
-1.6%
3,12
63.981 USD
|
20.535
-1.6%
|
3,12
|
63.981 USD
|
|
|
2024-05-01 |
2024-04-29 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
6.403
-0.5%
3,25
20.792 USD
|
6.403
-0.5%
|
3,25
|
20.792 USD
|
|
|
2024-04-24 |
2024-04-24 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
8.064
-0.6%
3,50
28.251 USD
|
8.064
-0.6%
|
3,50
|
28.251 USD
|
|
|
2024-04-24 |
2024-04-23 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
22.000
-1.7%
3,49
76.800 USD
|
22.000
-1.7%
|
3,49
|
76.800 USD
|
|
|
2024-04-24 |
2024-04-22 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
14.331
-1.1%
3,53
50.597 USD
|
14.331
-1.1%
|
3,53
|
50.597 USD
|
|
|
2024-04-18 |
2024-04-17 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
22.737
-1.7%
3,71
84.425 USD
|
22.737
-1.7%
|
3,71
|
84.425 USD
|
|
|
2024-04-18 |
2024-04-16 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
48.683
-3.5%
3,53
171.802 USD
|
48.683
-3.5%
|
3,53
|
171.802 USD
|
|
|
2023-12-18 |
2023-12-15 |
V
Verkauf
|
Yu Yong
VP, Clinical Trial Operations
Führungsperson
|
5.803
-100.0%
14,18
82.265 USD
|
5.803
-100.0%
|
14,18
|
82.265 USD
|
|
|
2023-12-18 |
2023-12-15 |
V
Verkauf
|
Yu Yong
VP, Clinical Trial Operations
Führungsperson
|
26.732
-82.2%
12,94
345.915 USD
|
26.732
-82.2%
|
12,94
|
345.915 USD
|
|
|
2023-12-14 |
2023-12-13 |
V
Verkauf
|
Thomas John
Nicht geschäftsführender Verwaltungsratsmitglied
|
1.927
-0.4%
13,93
26.839 USD
|
1.927
-0.4%
|
13,93
|
26.839 USD
|
|
|
2023-12-14 |
2023-12-13 |
V
Verkauf
|
Thomas John
Nicht geschäftsführender Verwaltungsratsmitglied
|
7.073
-1.5%
13,23
93.548 USD
|
7.073
-1.5%
|
13,23
|
93.548 USD
|
|
|
2023-12-14 |
2023-12-13 |
V
Verkauf
|
Tyree James L
Nicht geschäftsführender Verwaltungsratsmitglied
|
3.347
-49.2%
13,73
45.963 USD
|
3.347
-49.2%
|
13,73
|
45.963 USD
|
|
|
2023-12-14 |
2023-12-13 |
V
Verkauf
|
Tyree James L
Nicht geschäftsführender Verwaltungsratsmitglied
|
5.653
-45.4%
12,91
73.006 USD
|
5.653
-45.4%
|
12,91
|
73.006 USD
|
|
|
2023-12-08 |
2023-12-07 |
V
Verkauf
|
Yu Yong
VP, Clinical Trial Operations
Führungsperson
|
36.800
-53.1%
11,85
435.995 USD
|
36.800
-53.1%
|
11,85
|
435.995 USD
|
|
|
2023-11-22 |
2023-11-21 |
V
Verkauf
|
Yu Yong
VP, Clinical Trial Operations
Führungsperson
|
18.665
-21.2%
10,26
191.555 USD
|
18.665
-21.2%
|
10,26
|
191.555 USD
|
|
|
2023-11-21 |
2023-11-20 |
V
Verkauf
|
Yu Yong
VP, Clinical Trial Operations
Führungsperson
|
14.594
-14.2%
11,26
164.261 USD
|
14.594
-14.2%
|
11,26
|
164.261 USD
|
|
|
2023-11-21 |
2023-11-17 |
V
Verkauf
|
Yu Yong
VP, Clinical Trial Operations
Führungsperson
|
3.541
-3.3%
13,04
46.170 USD
|
3.541
-3.3%
|
13,04
|
46.170 USD
|
|
|
2023-10-26 |
2023-10-25 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
5.704
-0.4%
19,40
110.638 USD
|
5.704
-0.4%
|
19,40
|
110.638 USD
|
|
|
2023-10-25 |
2023-10-24 |
GV
Geplanter Verkauf
|
Yu Yong
VP, Clinical Trial Operations
Führungsperson
|
5.200
-4.7%
19,11
99.351 USD
|
5.200
-4.7%
|
19,11
|
99.351 USD
|
|
|
2023-10-25 |
2023-10-23 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
49.987
-3.5%
19,97
998.365 USD
|
49.987
-3.5%
|
19,97
|
998.365 USD
|
|
|
2023-10-16 |
2023-10-16 |
GV
Geplanter Verkauf
|
Thomas John
Nicht geschäftsführender Verwaltungsratsmitglied
|
881
-0.2%
21,30
18.769 USD
|
881
-0.2%
|
21,30
|
18.769 USD
|
|
|
2023-10-16 |
2023-10-16 |
GV
Geplanter Verkauf
|
Thomas John
Nicht geschäftsführender Verwaltungsratsmitglied
|
2.452
-0.5%
20,50
50.269 USD
|
2.452
-0.5%
|
20,50
|
50.269 USD
|
|
|
2023-10-11 |
2023-10-10 |
GV
Geplanter Verkauf
|
Yu Yong
VP, Clinical Trial Operations
Führungsperson
|
400
-0.4%
22,91
9.162 USD
|
400
-0.4%
|
22,91
|
9.162 USD
|
|
|
2023-10-11 |
2023-10-10 |
GV
Geplanter Verkauf
|
Yu Yong
VP, Clinical Trial Operations
Führungsperson
|
4.800
-4.3%
21,94
105.300 USD
|
4.800
-4.3%
|
21,94
|
105.300 USD
|
|
|
2023-10-10 |
2023-10-05 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
985
-0.1%
25,47
25.090 USD
|
985
-0.1%
|
25,47
|
25.090 USD
|
|
|
2023-10-10 |
2023-10-05 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
13.266
-0.9%
24,89
330.139 USD
|
13.266
-0.9%
|
24,89
|
330.139 USD
|
|
|
2023-10-04 |
2023-10-03 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
75.690
-5.0%
25,49
1.929.225 USD
|
75.690
-5.0%
|
25,49
|
1.929.225 USD
|
|
|
2023-09-29 |
2023-09-28 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
2.289
-0.2%
24,12
55.211 USD
|
2.289
-0.2%
|
24,12
|
55.211 USD
|
|
|
2023-09-29 |
2023-09-27 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
11.257
-0.7%
24,47
275.459 USD
|
11.257
-0.7%
|
24,47
|
275.459 USD
|
|
|
2023-09-27 |
2023-09-26 |
GV
Geplanter Verkauf
|
Yu Yong
VP, Clinical Trial Operations
Führungsperson
|
2.203
-2.0%
24,46
53.890 USD
|
2.203
-2.0%
|
24,46
|
53.890 USD
|
|
|
2023-09-27 |
2023-09-26 |
GV
Geplanter Verkauf
|
Yu Yong
VP, Clinical Trial Operations
Führungsperson
|
1.114
-1.0%
23,51
26.195 USD
|
1.114
-1.0%
|
23,51
|
26.195 USD
|
|
|
2023-09-27 |
2023-09-26 |
GV
Geplanter Verkauf
|
Yu Yong
VP, Clinical Trial Operations
Führungsperson
|
1.883
-1.7%
22,54
42.442 USD
|
1.883
-1.7%
|
22,54
|
42.442 USD
|
|
|
2023-09-27 |
2023-09-26 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
9.600
-0.6%
24,51
235.296 USD
|
9.600
-0.6%
|
24,51
|
235.296 USD
|
|
|
2023-09-27 |
2023-09-26 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
12.740
-0.8%
24,03
306.142 USD
|
12.740
-0.8%
|
24,03
|
306.142 USD
|
|
|
2023-09-27 |
2023-09-26 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
7.465
-0.5%
22,47
167.739 USD
|
7.465
-0.5%
|
22,47
|
167.739 USD
|
|
|
2023-09-27 |
2023-09-25 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
1.100
-0.1%
27,81
30.591 USD
|
1.100
-0.1%
|
27,81
|
30.591 USD
|
|
|
2023-09-27 |
2023-09-25 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
1.900
-0.1%
26,60
50.540 USD
|
1.900
-0.1%
|
26,60
|
50.540 USD
|
|
|
2023-09-27 |
2023-09-25 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
5.511
-0.4%
25,75
141.908 USD
|
5.511
-0.4%
|
25,75
|
141.908 USD
|
|
|
2023-09-27 |
2023-09-25 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
3.947
-0.3%
24,82
97.965 USD
|
3.947
-0.3%
|
24,82
|
97.965 USD
|
|
|
2023-09-25 |
2023-09-22 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
4.621
-0.3%
27,76
128.270 USD
|
4.621
-0.3%
|
27,76
|
128.270 USD
|
|
|
2023-09-25 |
2023-09-22 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
4.421
-0.3%
26,88
118.853 USD
|
4.421
-0.3%
|
26,88
|
118.853 USD
|
|
|
2023-09-25 |
2023-09-21 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
4.678
-0.3%
28,82
134.815 USD
|
4.678
-0.3%
|
28,82
|
134.815 USD
|
|
|
2023-09-25 |
2023-09-21 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
2.871
-0.2%
27,89
80.063 USD
|
2.871
-0.2%
|
27,89
|
80.063 USD
|
|
|
2023-09-21 |
2023-09-20 |
GV
Geplanter Verkauf
|
Yu Yong
VP, Clinical Trial Operations
Führungsperson
|
6.000
-5.4%
27,96
167.786 USD
|
6.000
-5.4%
|
27,96
|
167.786 USD
|
|
|
2023-09-21 |
2023-09-20 |
GV
Geplanter Verkauf
|
Ryder Sean
General Counsel
Führungsperson
|
10.000
-94.6%
30,00
300.000 USD
|
10.000
-94.6%
|
30,00
|
300.000 USD
|
|
|
2023-09-20 |
2023-09-19 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
8.247
-100.0%
27,16
223.979 USD
|
8.247
-100.0%
|
27,16
|
223.979 USD
|
|
|
2023-09-20 |
2023-09-19 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
23.920
-74.4%
26,21
626.962 USD
|
23.920
-74.4%
|
26,21
|
626.962 USD
|
|
|
2023-09-20 |
2023-09-18 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
2.927
-36.9%
24,17
70.754 USD
|
2.927
-36.9%
|
24,17
|
70.754 USD
|
|
|
2023-09-20 |
2023-09-18 |
V
Verkauf
|
Szalay Aladar
Large shareholder
|
27.365
-77.5%
23,20
634.895 USD
|
27.365
-77.5%
|
23,20
|
634.895 USD
|
|
